Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (Anakinra) [6]

Clinical and Experimental Rheumatology

Volumn 25, Issue 1, 2007, Pages 119-

  Koné Paut, Isabelle ^a   Retornaz, K ^a,b   Garnier, J M ^a,b   Bader Meunier, B ^a  

^a BICÊTRE HOSPITAL   (France)

^b CNRS Marseille Universities   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CYCLOSPORIN; ETANERCEPT; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID;

BLOOD CULTURE; BONE MARROW EXAMINATION; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FRANCE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; LEISHMANIA INFANTUM; LETTER; POLYARTHRITIS; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; VISCERAL LEISHMANIASIS;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LEISHMANIASIS, VISCERAL;

EID: 33947587062     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (11)

1. QUARTIER P, TAUPIN P, BOURDEAUT F et al.: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003, 48: 1093-101.
2. VERBSKY JW, WHITE AJ: Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 2071-5.
3. PASCUAL V, ALLANTAZ F, ARCE E, PUNARO M, BRANCHEREAU J: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86,
4. MOHAN AK, COTE TR, BLOCK JA, MANADAN AM, SIEGEL JN, BROWN MM: Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39: 295-9.
5. COHEN SB, MORELAND IW, CUSH JJ et al.: A multicenter double blind placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004; 63: 1062-8.
6. FABRE S, GIBERT C, LECHICHE C, DEREURE J, JORGENSEN C, SNNY J: Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol 2005; 23: 891-2.
7. ROMANI-COSTA V, SANCHEZ C, MOYA F, ESTANI C: Visceral leishmaniasis related to infliximab administration. Enferm Infecc Microbiol Clin 2004; 22: 310.
8. MINODIER P, PIARROUX R, GARNIER JM, UNAL D, PERRIMOND H, DUMON H: Pediatric visceral leishmaniasis in southern France. Pediatr Infect Dis 1998; 17: 701-4.
9. STÉPHAN JL, KONÉ-PAUT I, GALAMBRUN C, MOUY R, BADER-MEUNIER B, PRIEUR AM: Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 2001; 40: 1285-92.
10. MULLER K, HERNER EB, STAGG A, BENDZEN K, WOO P: Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br J Rheumatol 1998; 37: 562-9.
11. HO JL, BADARO R, SCHWARTZ A et al,: Diminished in vitro production of interleukin-1 and tumor necrosis factor-alpha during acute visceral leishmaniasis and recovery after therapy. J Infect Dis 1992; 165: 1094-102.